Make Informed Investment Decisions with Affordable Access to Experts
Exploring IMMU-132 (Sacituzumab govitecan) and its place in the IO landscape in treating metastatic triple negative breast cancerTicker(s): IMMU, MRK
Name: Dr Foluso Ademuyiwa - MD
- Medical oncologist at Washington University in St. Louis whose research focuses on developing novel treatments for patients with triple negative breast cancer (TNBC).
- Treats ~150 patients with HER2-positive breast cancer (total) & 15 patients with triple negative breast cancer per week.
- Principal Investigator on an NIH-funded clinical trial investigating a unique chemotherapy combination in the pre-operative setting in patients with TNBC.
Please describe your clinical practice; roughly how many patients with triple negative breast cancer do you currently treat?
What were your impressions on the data presented at SABCS for Sacituzumab govitecan (IMMU-132)?Added By: c_admin
If approved, how do you see IMMU-132 competing in the IO landscape? How does it compare to Keytruda?Added By: c_admin
On a scale of 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.